PTC Therapeutics To Present New Sephience Data At The 2026 Society For The Study Of Inborn Errors Of Metabolism Annual Symposium, August 25-28
The presentations include new data from clinical trials and real-world evidence which reinforce the clinically meaningful benefits of Sephience on lowering phenylalanine (Phe), significant diet liberalization and
PTC Therapeutics will share new test results showing their medicine Sephience helps patients with a rare disease feel better and eat more freely. When a company presents good study results at a big medical meeting, it can show people that the medicine is working as hoped.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.